Integral Health Asset Management LLC Grows Stock Holdings in Oscar Health, Inc. $OSCR

Key Points

• Integral Health Asset Management LLC increased its stake in Oscar Health by 450% in Q3, buying 450,000 shares to own 550,000 shares (about 0.21% of the company) valued at roughly $10.41 million.
• Insider selling continues: Mario Schlosser sold 23,038 shares on Jan 8 (a 6.17% reduction), insiders sold 138,835 shares last quarter and now own 24.39% of Oscar, while institutions hold 75.70%.
• Oscar Health reported an EPS miss of ($1.24) vs. ($0.92) consensus and revenue of $2.81B vs. $3.12B, leaving negative profitability; analysts are mixed with an average "Hold" rating and $16.88 target as the stock trades near $13.22.

Integral Health Asset Management LLC lifted its stake in Oscar Health, Inc. (NYSE:OSCR - Free Report) by 450.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 550,000 shares of the company's stock after purchasing an additional 450,000 shares during the quarter. Integral Health Asset Management LLC owned about 0.21% of Oscar Health worth $10,412,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Farther Finance Advisors LLC increased its position in Oscar Health by 4,420.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,311 shares of the company's stock valued at $25,000 after buying an additional 1,282 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in Oscar Health by 7,473.3% in the first quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company's stock worth $30,000 after acquiring an additional 2,242 shares in the last quarter. Strs Ohio purchased a new stake in shares of Oscar Health in the first quarter worth $30,000. Tsfg LLC purchased a new stake in shares of Oscar Health in the third quarter worth $38,000. Finally, EMC Capital Management bought a new position in shares of Oscar Health during the second quarter valued at $64,000. Hedge funds and other institutional investors own 75.70% of the company's stock.

Insider Activity

In other news, insider Mario Schlosser sold 23,038 shares of Oscar Health stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $17.65, for a total value of $406,620.70. Following the completion of the sale, the insider directly owned 350,180 shares in the company, valued at $6,180,677. The trade was a 6.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 138,835 shares of company stock worth $2,298,269. Company insiders own 24.39% of the company's stock.

Oscar Health Trading Up 1.7%

Shares of NYSE:OSCR opened at $13.22 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.96 and a quick ratio of 0.96. Oscar Health, Inc. has a 1 year low of $11.20 and a 1 year high of $23.80. The company has a market cap of $3.93 billion, a P/E ratio of -7.59 and a beta of 1.91. The stock's fifty day moving average price is $14.53 and its 200-day moving average price is $16.47.

Oscar Health (NYSE:OSCR - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.32). Oscar Health had a negative return on equity of 39.35% and a negative net margin of 3.79%.The business had revenue of $2.81 billion during the quarter, compared to the consensus estimate of $3.12 billion. During the same quarter in the previous year, the business posted ($0.62) earnings per share. Oscar Health's quarterly revenue was up 17.3% compared to the same quarter last year. Sell-side analysts expect that Oscar Health, Inc. will post 0.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Piper Sandler raised Oscar Health from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $13.00 to $25.00 in a research report on Tuesday, November 25th. UBS Group restated a "neutral" rating and set a $15.00 price objective on shares of Oscar Health in a research note on Wednesday, February 11th. Wall Street Zen raised shares of Oscar Health from a "sell" rating to a "hold" rating in a report on Saturday, February 14th. Barclays set a $18.00 target price on shares of Oscar Health and gave the stock an "equal weight" rating in a research note on Monday, January 5th. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Oscar Health in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Oscar Health has an average rating of "Hold" and an average target price of $16.88.

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company's primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.